[Current guidelines on carotid artery stenting. Critical evaluation].
1Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin, Städtisches Klinikum München GmbH, Klinikum Neuperlach, Oskar-Maria-Graf-Ring 51, 81737, München, Deutschland.
Herz
|October 31, 2013
Summary
Current guidelines for carotid artery stenosis treatment conflict due to data interpretation. More research is needed to determine the optimal therapy comparing medical, surgical, and endovascular interventions.
Area of Science:
- Cardiovascular Medicine
- Interventional Neurology
- Evidence-Based Medicine
Background:
- Current guidelines for carotid artery stenosis treatment are based on interdisciplinary discussions and selective interpretation of European studies.
- Conflicting recommendations exist, particularly when comparing surgical interventions with carotid artery stenting (CAS).
Purpose of the Study:
- To highlight the discrepancies in current guidelines regarding carotid artery stenosis treatment.
- To identify the challenges in conducting new comparative studies for carotid artery disease therapy.
Main Methods:
- Analysis of existing European randomized studies and current international guidelines (ESC, American guidelines, German Society of Cardiology comments).
- Discussion of the limitations in evidence-based medicine and the difficulties in designing new, large-scale randomized trials.
Main Results:
- Surgical guidelines suggest CAS only for specific symptomatic patients with disadvantages or comorbidities.
- ESC guidelines recommend CAS for high-risk patients if outcomes match surgery, while American guidelines equate CAS and carotid endarterectomy (CEA) assuming similar complication rates.
- Differential data interpretation leads to varied recommendations, with a lack of definitive comparative studies.
Conclusions:
- The optimal treatment for carotid artery disease remains unclear due to inadequate data and conflicting interpretations.
- Challenges in funding, patient recruitment, and the rapid evolution of techniques hinder the development of new, conclusive randomized trials.


